Hot Investor Mandate: Family Office Focuses On New Treatments For Eye Diseases and Cancer

21 Mar

A family office based in the USA is looking to invest in technologies related to ophthalmology and oncology that are in the pre-clinical to PhI stages, and will generally invest $5-10M in series A rounds. The firm is willing to invest globally, with a special interest in companies based in North America, Europe and China.

The firm is interested in therapeutics, medical device and diagnostics companies with technologies in the ophthalmology and oncology spaces. The firm may consider digital health companies as well. For ophthalmology-related companies, the firm is most interested in small molecules or combination devices. For oncology-related companies, the firm prefers I/O technologies or diagnostics.

The firm prefers to take a board seat after investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

One Response to “Hot Investor Mandate: Family Office Focuses On New Treatments For Eye Diseases and Cancer”

  1. Dan Conley March 21, 2019 at 3:09 pm #

    Yes, I’m a co-investor in ophthalmology and preventing blindness mandates. Please let’s connect. Dan Conley c.908.917.3537

Leave a Reply to Dan Conley Cancel reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: